STOCK TITAN

Bristol-Myers Squibb Co. - BMY STOCK NEWS

Welcome to our dedicated page for Bristol-Myers Squibb Co. news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co. stock.

Bristol-Myers Squibb Co. (BMY) is a renowned American multinational pharmaceutical company headquartered in New York City. As one of the largest pharmaceutical companies globally, Bristol-Myers Squibb (BMS) consistently ranks on the Fortune 500 list. In fiscal 2022, the company achieved total revenue of $46.2 billion.

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs across various therapeutic areas, including cardiovascular, cancer, and immune disorders. A significant area of focus for BMS is immuno-oncology, where it has established itself as a leader in drug development. Approximately 70% of BMS's total sales are derived from the U.S. market, reflecting its higher dependence on this region compared to its peers.

Recent achievements and collaborations highlight BMS's commitment to innovation and partnerships. On May 22, 2024, BMS joined NeoPhore Limited's oversubscribed Series B extension round. This additional investment will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (MMR) pathway in cancer, and further advance its pre-clinical studies. NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.

Another noteworthy collaboration was announced on June 5, 2024, with I-Mab, a U.S.-based global biotech company. This partnership will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody, with BMS's immune checkpoint inhibitor, nivolumab, and chemotherapy. The study, a multi-national Phase 1, will focus on advanced Claudin 18.2-positive gastric and esophageal cancers. BMS will supply nivolumab, which is designed to enhance T-cell function and improve anti-tumor responses.

Additionally, on June 5, 2024, Envisagenics, an AI-driven biotechnology company, announced a Series B fundraising round with participation from BMS. This funding will be utilized to further develop Envisagenics' pipeline of novel preclinical oncology assets using their cloud-based AI drug discovery platform, SpliceCore®. This collaboration underscores BMS's continued investment in innovative technologies and therapeutics.

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Through strategic partnerships, cutting-edge research, and a commitment to therapeutic advancements, BMS continues to make significant strides in the biopharmaceutical industry.

Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) announced that the FDA has granted accelerated approval for Augtyro™ (repotrectinib), a new tyrosine kinase inhibitor (TKI), for treating NTRK-positive solid tumors in patients aged 12 and older. This approval is based on Phase 1/2 TRIDENT-1 trial results, showing significant response rates in both TKI-naïve and TKI-pretreated patients.

Among TKI-naïve patients, 58% had a confirmed objective response with a median follow-up of 17.8 months. In TKI-pretreated patients, the overall response rate was 50%. Intracranial responses were also noted in patients with CNS metastases. Augtyro showed manageable safety profiles, though notable adverse events included dizziness, hepatotoxicity, and pneumonitis.

Continued approval may depend on further confirmatory trials. This is the second indication for Augtyro in the U.S., following its approval for ROS1-positive NSCLC in November 2023. The recommended dosage is 160 mg daily for the first 14 days, then twice daily until disease progression or unacceptable toxicity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
-
Rhea-AI Summary

Envisagenics, a biotechnology company specializing in RNA splicing therapeutics, has completed a Series B funding round. The round included existing investors Third Kind Venture Capital, Empire State Development, and Red Cell Partners, along with new strategic investor Bristol Myers Squibb (NYSE: BMY).

The funds will be used to advance Envisagenics' pipeline of preclinical oncology assets using its AI drug discovery platform, SpliceCore®. This platform integrates machine learning and high-performance computing to identify novel splicing isoforms.

Envisagenics has collaborations with Biogen, the Lung Cancer Initiative at Johnson & Johnson, and Bristol Myers Squibb. CEO Maria Luisa Pineda stated that the funding will aid in developing immunotherapies and disease-modifying ASOs for neurodegenerative diseases. The goal is to advance their first asset into clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
AI
-
Rhea-AI Summary

I-Mab (NASDAQ: IMAB), a global biotech company, has announced a clinical trial collaboration with Bristol Myers Squibb (NYSE: BMY). The focus is on evaluating the combination of givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, with nivolumab and chemotherapy for treating advanced gastric and esophageal cancers. The collaboration leverages promising safety and efficacy data from givastomig's monotherapy study, presented at the European Society of Medical Oncology Congress 2023. The multi-national Phase 1 study will be conducted by I-Mab, with Bristol Myers Squibb supplying nivolumab. The aim is to explore the potential of this combination as a first-line treatment for Claudin 18.2-positive cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
Rhea-AI Summary

Bristol Myers Squibb announced the first presentation of Phase 3 CheckMate -9DW trial results showing the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves overall survival (OS) and objective response rate (ORR) in patients with advanced hepatocellular carcinoma (HCC) compared to lenvatinib or sorafenib.

Median OS for Opdivo plus Yervoy was 23.7 months versus 20.6 months for lenvatinib or sorafenib. The ORR for Opdivo plus Yervoy was 36%, more than double the 13% for lenvatinib or sorafenib, with a median duration of response of 30 months versus 12.9 months.

The ASCO Annual Meeting will feature these results, highlighting a reduced risk of symptom deterioration and a manageable safety profile.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
none
-
Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. CEO and Board Chair Christopher Boerner, Ph.D., will partake in a fireside chat on June 11, 2024, starting at 11:20 a.m. ET. Investors and the public can listen via a live webcast accessible through the company's investor relations website. An archived version will be available post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
conferences
-
Rhea-AI Summary

Bristol Myers Squibb's Breyanzi has shown significant clinical benefits for patients with various B-cell malignancies, according to new data presented at the 2024 ASCO Annual Meeting. The three-year follow-up from the Phase 3 TRANSFORM trial demonstrates sustained event-free survival and durable responses in patients with large B-cell lymphoma (LBCL), outperforming standard care.

The study also highlights Breyanzi's consistent efficacy and safety in mantle cell lymphoma (MCL) and follicular lymphoma (FL) across different subgroups, regardless of the number of prior treatments or use of bridging therapy. This underscores Breyanzi's potential for earlier lines of treatment and relapsed or refractory cases. Recently, the FDA granted accelerated approval for Breyanzi in relapsed or refractory FL and MCL, expanding its use across four types of B-cell lymphomas.

These findings emphasize Breyanzi's role as a transformative CAR T cell therapy with a robust clinical profile, offering hope for improved patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
Rhea-AI Summary

Bristol Myers Squibb presented multiple analyses at the 2024 ASCO Annual Meeting showcasing Opdivo and Opdivo-based combinations for non-small cell lung cancer (NSCLC).

Key findings include: improved event-free survival and pathologic complete response in stage III resectable NSCLC patients from the CheckMate -77T study; four-year survival data from CheckMate -816 showing enhanced event-free survival with neoadjuvant Opdivo plus chemotherapy; and five-year data from CheckMate -9LA indicating survival benefits with Opdivo plus Yervoy and chemotherapy in metastatic NSCLC patients.

Additional studies showed promising results for Augtyro and KRAZATI in specific NSCLC patient subsets. No new safety concerns were noted across these studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
-
Rhea-AI Summary

Bristol Myers Squibb announced that KRAZATI (adagrasib) showed a statistically significant improvement in progression-free survival (PFS) for patients with pretreated locally advanced or metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) compared to standard chemotherapy in the Phase 3 KRYSTAL-12 study. Median PFS was 5.5 months for KRAZATI versus 3.8 months for chemotherapy. The overall response rate (ORR) was 32% with KRAZATI compared to 9% for chemotherapy. KRAZATI also demonstrated a higher intracranial response rate in patients with CNS metastases. The safety profile of KRAZATI was consistent with known data, with treatment-related adverse events reported in a high percentage of patients. These results will be presented at the 2024 ASCO Annual Meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) has received FDA approval for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CAR T cell therapy targeting relapsed or refractory mantle cell lymphoma (MCL). This marks the fourth subtype of non-Hodgkin lymphoma for which Breyanzi is approved. In the TRANSCEND NHL 001 trial, Breyanzi demonstrated an 85.3% response rate, with a 67.6% complete response rate in patients who had at least two prior lines of systemic therapy, including a BTK inhibitor. The treatment involves a one-time infusion and has shown a consistent safety profile, making it an option for outpatient management. Despite high rates of response, significant risks such as Cytokine Release Syndrome (CRS) and neurologic toxicities persist. The approval extends Breyanzi's reach in treating B-cell malignancies, offering new hope for patients with options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Bristol Myers Squibb announced European Commission approval for Opdivo® (nivolumab) combined with cisplatin and gemcitabine for first-line treatment of unresectable or metastatic urothelial carcinoma (UC). The approval was based on the CheckMate -901 Phase 3 trial, which demonstrated that the combination improved overall survival and progression-free survival compared to chemotherapy alone.

Results from the trial showed a 22% reduction in the risk of death and a 28% reduction in the risk of disease progression or death. The combination also resulted in a higher overall response rate of 57.6% versus 43.1% with chemotherapy alone. These findings position Opdivo with chemotherapy as a new standard of care for this patient population in the EU.

Serious adverse reactions affected 48% of patients, with common side effects including nausea, fatigue, and musculoskeletal pain. The combination treatment has been approved for use in all 27 EU member states, as well as Iceland, Liechtenstein, and Norway.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
none

FAQ

What is the current stock price of Bristol-Myers Squibb Co. (BMY)?

The current stock price of Bristol-Myers Squibb Co. (BMY) is $54.32 as of November 1, 2024.

What is the market cap of Bristol-Myers Squibb Co. (BMY)?

The market cap of Bristol-Myers Squibb Co. (BMY) is approximately 111.1B.

What is Bristol-Myers Squibb's core business?

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs for various therapeutic areas, including cardiovascular, cancer, and immune disorders.

Where is Bristol-Myers Squibb headquartered?

Bristol-Myers Squibb is headquartered in New York City, USA.

What was Bristol-Myers Squibb's revenue for fiscal 2022?

Bristol-Myers Squibb reported a total revenue of $46.2 billion for fiscal 2022.

What is a significant focus area for Bristol-Myers Squibb?

A significant focus area for Bristol-Myers Squibb is immuno-oncology, where it is a leader in drug development.

How much of Bristol-Myers Squibb's total sales come from the U.S. market?

Approximately 70% of Bristol-Myers Squibb's total sales are derived from the U.S. market.

What recent collaboration did Bristol-Myers Squibb announce with NeoPhore Limited?

On May 22, 2024, Bristol-Myers Squibb joined NeoPhore Limited's Series B extension round to explore novel biology associated with the DNA mismatch repair pathway in cancer.

What is the purpose of Bristol-Myers Squibb's collaboration with I-Mab?

The collaboration with I-Mab focuses on evaluating the combination of givastomig with BMS's nivolumab and chemotherapy for advanced Claudin 18.2-positive gastric and esophageal cancers.

What is SpliceCore®?

SpliceCore® is Envisagenics' cloud-based AI drug discovery platform that integrates machine learning algorithms to identify novel and disease-specific RNA splicing isoforms.

When did Bristol-Myers Squibb participate in Envisagenics' Series B fundraising round?

Bristol-Myers Squibb participated in Envisagenics' Series B fundraising round announced on June 5, 2024.

What is Bristol-Myers Squibb's mission?

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.

Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

BMY Stock Data

111.11B
2.03B
0.11%
79.38%
1.11%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
PRINCETON